HARVEST reports comparable acute toxicity with three-week regional nodal irradiation in breast cancer

In 801 node-positive breast cancer patients, three-week comprehensive regional nodal IMRT showed similar overall acute toxicity and less grade ≥2 dermatitis.

KEY POINTS

  • HARVEST (NCT03829553) is a multicenter randomized phase III trial conducted across eight Chinese centers, enrolling 801 patients with pT1–3, node-positive invasive breast cancer following mastectomy or breast-conserving surgery. Patients were randomized to hypofractionated radiotherapy (400 patients) or conventional fractionation (401 patients). All received IMRT encompassing the chest wall or whole breast and comprehensive regional nodal irradiation, including the internal mammary nodes (IMNs).
  • Hypofractionated treatment delivered 40.05 Gy in 15 fractions versus 50 Gy in 25 fractions with conventional treatment. Following breast-conserving surgery, sequential tumor-bed boosts of 10.68 Gy in four fractions and 10 Gy in five fractions were prescribed, respectively. The trial's primary endpoint is five-year locoregional recurrence, which has not yet been reported. The current analysis focuses on protocol compliance, acute toxicity, preliminary late toxicity, and cosmetic outcomes.
  • Overall grade ≥2 acute toxicity was not significantly different between arms. Across both groups, 77/801 patients (9.6%) experienced grade ≥2 acute radiation-related toxicity, with a relative risk of 0.79 (95% CI 0.52–1.22; p=0.29) for hypofractionation versus conventional fractionation. Five patients (0.6%) developed grade 3 acute toxicity, including two after hypofractionation and three after conventional RT. No significant between-arm differences were identified for pneumonitis, fatigue, breast pain, dysphagia, or breast edema.
  • Hypofractionation significantly reduced moderate acute dermatitis, with a relative risk of 0.48 (95% CI 0.25–0.92; p=0.03) and an absolute risk difference of −3.48 percentage points. At treatment completion, grade ≥2 dermatitis occurred in 1.3% versus 5.2% (p<0.01), but the temporal pattern differed: dermatitis after hypofractionation peaked later, reaching 2.3% at four weeks, compared with 3.0% after conventional RT. This highlights the importance of assessing acute skin toxicity beyond the final treatment fraction.
  • Most dosimetric objectives were achieved, although IMN coverage was less complete than other target regions. Using the commonly applied criterion of PTV D95% exceeding 95% of prescription, overall target compliance exceeded 98.5% in both arms. However, only 69.0% of hypofractionated plans and 62.8% of conventional plans achieved this threshold for the IMN PTV. In left-sided patients, median heart mean dose expressed as EQD2 was 4.54 versus 5.19 Gy, respectively, with acceptable compliance for most prespecified OAR constraints.
  • Breast cosmetic outcomes were comparable through three years in the evaluable subgroup. Among 188 breast-conserving patients, photographic assessment was available for 123 (65.4%) at three years. Patient-reported excellent cosmesis occurred in 78.5% after hypofractionation versus 74.1% after conventional RT (p=0.53), while physician assessments showed no significant difference. At median follow-up of 38.1 months, no grade 3 late toxicity was reported, and grade ≥2 late events, including breast induration, lung fibrosis, lymphedema, and shoulder dysfunction, were not significantly different between groups.
  • The findings support short-term tolerability but do not establish long-term oncological equivalence. Although the study is randomized and large, its primary endpoint, mature late toxicity, reconstruction-related outcomes, and quality-of-life results remain pending. Only 234 hypofractionated and 212 conventionally treated patients had completed full three-year follow-up, and toxicity comparisons were not adjusted for multiple testing. Incomplete IMN coverage also indicates a meaningful trade-off between elective nodal target coverage and OAR sparing.

CLINICAL TAKEAWAY

Three-week comprehensive regional nodal IMRT, including internal mammary irradiation, demonstrated comparable early toxicity and cosmetic outcomes to conventional five-week treatment, with less moderate acute dermatitis. These findings provide randomized support for the short-term tolerability and technical feasibility of hypofractionated nodal irradiation in node-positive breast cancer. However, mature locoregional control and late toxicity results are still required before definitive conclusions about long-term equivalence.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction